AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jun 12, 2015

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., June 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with relapsed/refractory chronic lymphocytic leukemia (CLL) taking venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab, had an overall response rate (ORR) of 84 percent (n=41/49).1 Additionally, six patients stopped venetoclax after achieving either a complete response (CR) or CR with incomplete marrow recovery (CRi). Three patients maintained a response after a median of 12 months (0-21). These data were detailed in an oral presentation at the 20th Congress of the European Hematology Association (EHA), June 11-15, in Vienna.

Jun 09, 2015

AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with Severe Chronic Plaque Psoriasis at the 23rd World Congress of Dermatology

- Results show HUMIRA is safe and effective for the treatment of severe chronic plaque psoriasis in pediatric patients

Jun 08, 2015

AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress

NORTH CHICAGO, Ill., June 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy medicines at the 20th European Hematology Association Annual Congress (EHA), June 11-14, in Vienna. Notable data include an oral presentation of venetoclax, an investigational B-cell lymphoma-2 (BCL-2) selective inhibitor, in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (R/R CLL) patients.

Jun 08, 2015

AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally

NORTH CHICAGO, Ill., June 8, 2015 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees globally volunteering more than 14,000 service hours to transform schools and communities where AbbVie employees live and work.

Jun 05, 2015

AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., June 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10 a.m. Central time.

Jun 04, 2015

AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015

NORTH CHICAGO, Ill., June 4, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that data from more than 30 abstracts on HUMIRA® (adalimumab), investigational medicines and rheumatologic diseases will be presented at the 16th European League Against Rheumatism Annual Congress (EULAR), June 10 - 13 in Rome. Abstracts to be presented include data from a Phase 3 pivotal trial evaluating the efficacy and safety of HUMIRA as an investigational treatment for patients with non-infectious intermediate, posterior, or panuveitis, insights into the real-world impact of rheumatologic diseases, and new research on AbbVie's investigational medicines for rheumatoid arthritis, knee osteoarthritis and lupus.   

Jun 01, 2015

AbbVie to Present at Jefferies 2015 Healthcare Conference

NORTH CHICAGO, Ill., June 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015. Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at 8:30 a.m. Central time.

Jun 01, 2015

AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., June 1, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers. These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago. Veliparib is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor being evaluated for the treatment of various cancer types, including NSCLC.

May 31, 2015

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., May 31, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

May 26, 2015

AbbVie Completes Acquisition of Pharmacyclics

NORTH CHICAGO, Ill., May 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 billion global market.